PCI Biotech: Presentation of fimaChem for bile duct cancer at IPA masterclass series
08 nov. 2021 05h15 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 8 November 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that the coordinating principal investigator for the RELEASE trial, Prof. Dr. Jörg...
PCI Biotech receives Orphan Drug Designation in South Korea for fimaporfin in the treatment of bile duct cancer
28 mai 2021 08h51 HE
|
PCI Biotech Holding ASA
Oslo, 28 May 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that the Ministry of Food and Drug Safety (MFDS) in South Korea has granted Orphan Drug...
PCI Biotech: First patient enrolled in Asia in the fimaCHEM pivotal RELEASE study
26 oct. 2020 07h48 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 26 October 2020 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced...